CHATZIKONSTANTINOU, T., A. KAPETANAKIS, L. SCARFO, G. KARAKATSOULIS, D. ALLSUP, A. A. CABRERO, M. ANDRES, D. ANTIC, M. BAILE, P. BALIAKAS, D. BRON, A. CAPASSO, S. CHATZILEONTIADOU, R. CORDOBA, J.G. CORREA, C. CUELLAR-GARCIA, L. DE PAOLI, M. R. DE PAOLIS, G. DEL POETA, C. DEMOSTHENOUS, M. DIMOU, D. DONALDSON, Michael DOUBEK, M. EFSTATHOPOULOU, B. EICHHORST, S. EL-ASHWAH, A. ENRICO, B. ESPINET, L. FARINA, A. FERRARI, M. FOGLIETTA, H. FREDERIKSEN, M. FURSTENAU, J. A. GARCIA-MARCO, R. GARCIA-SERRA, M. GENTILE, E. GIMENO, A. GLENTHOJ, M. G. DA SILVA, O. GUTWEIN, Y. K. HAKOBYAN, Y. HERISHANU, J. A. HERNANDEZ-RIVAS, T. HEROLD, I. INNOCENTI, G. ITCHAKI, O. JAKSIC, A. JANSSENS, O. B. KALASHNIKOVA, E. KALICINSKA, L. K. KARLSSON, A. P. KATER, S. KERSTING, J. LABRADOR, D. LAD, L. LAURENTI, M. D. LEVIN, E. LISTA, A. LOPEZ-GARCIA, L. MALERBA, R. MARASCA, M. MARCHETTI, J. MARQUET, M. MATTSSON, F. R. MAURO, I. MILOSEVIC, F. MIRAS, M. MORAWSKA, M. MOTTA, T. MUNIR, R. MURRU, C. U. NIEMANN, R. N. RODRIGUES, J. OLIVIERI, L. ORSUCCI, M. PAPAIOANNOU, M. A. PAVLOVSKY, I. PISKUNOVA, V. M. POPOV, F. M. QUAGLIA, G. QUARESMINI, K. QVIST, G. REDA, G. M. RIGOLIN, R. RUCHLEMER, G. SAGHUMYAN, A. SHRESTHA, M. SIMKOVIC, M. SPACEK, P. SPORTOLETTI, O. STANCA, N. STAVROYIANNI, T. TADMOR, D. TE RAA, S. H. TONINO, L. TRENTIN, E. VAN DER SPEK, M. VAN GELDER, R. VAN KAMPEN, M. VARETTONI, A. VISENTIN, C. VITALE, E. WASIK-SZCZEPANEK, T. WROBEL, L. Y. SAN SEGUNDO, M. YASSIN, M. COSCIA, A. RAMBALDI, E. MONTSERRAT, R. FOA, A. CUNEO, K. STAMATOPOULOS and P. GHIA. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia. London: Nature Publishing Group, 2021, vol. 35, No 12, p. 3444-3454. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/s41375-021-01450-8.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
Authors CHATZIKONSTANTINOU, T., A. KAPETANAKIS, L. SCARFO, G. KARAKATSOULIS, D. ALLSUP, A. A. CABRERO, M. ANDRES, D. ANTIC, M. BAILE, P. BALIAKAS, D. BRON, A. CAPASSO, S. CHATZILEONTIADOU, R. CORDOBA, J.G. CORREA, C. CUELLAR-GARCIA, L. DE PAOLI, M. R. DE PAOLIS, G. DEL POETA, C. DEMOSTHENOUS, M. DIMOU, D. DONALDSON, Michael DOUBEK (203 Czech Republic, belonging to the institution), M. EFSTATHOPOULOU, B. EICHHORST, S. EL-ASHWAH, A. ENRICO, B. ESPINET, L. FARINA, A. FERRARI, M. FOGLIETTA, H. FREDERIKSEN, M. FURSTENAU, J. A. GARCIA-MARCO, R. GARCIA-SERRA, M. GENTILE, E. GIMENO, A. GLENTHOJ, M. G. DA SILVA, O. GUTWEIN, Y. K. HAKOBYAN, Y. HERISHANU, J. A. HERNANDEZ-RIVAS, T. HEROLD, I. INNOCENTI, G. ITCHAKI, O. JAKSIC, A. JANSSENS, O. B. KALASHNIKOVA, E. KALICINSKA, L. K. KARLSSON, A. P. KATER, S. KERSTING, J. LABRADOR, D. LAD, L. LAURENTI, M. D. LEVIN, E. LISTA, A. LOPEZ-GARCIA, L. MALERBA, R. MARASCA, M. MARCHETTI, J. MARQUET, M. MATTSSON, F. R. MAURO, I. MILOSEVIC, F. MIRAS, M. MORAWSKA, M. MOTTA, T. MUNIR, R. MURRU, C. U. NIEMANN, R. N. RODRIGUES, J. OLIVIERI, L. ORSUCCI, M. PAPAIOANNOU, M. A. PAVLOVSKY, I. PISKUNOVA, V. M. POPOV, F. M. QUAGLIA, G. QUARESMINI, K. QVIST, G. REDA, G. M. RIGOLIN, R. RUCHLEMER, G. SAGHUMYAN, A. SHRESTHA, M. SIMKOVIC, M. SPACEK, P. SPORTOLETTI, O. STANCA, N. STAVROYIANNI, T. TADMOR, D. TE RAA, S. H. TONINO, L. TRENTIN, E. VAN DER SPEK, M. VAN GELDER, R. VAN KAMPEN, M. VARETTONI, A. VISENTIN, C. VITALE, E. WASIK-SZCZEPANEK, T. WROBEL, L. Y. SAN SEGUNDO, M. YASSIN, M. COSCIA, A. RAMBALDI, E. MONTSERRAT, R. FOA, A. CUNEO, K. STAMATOPOULOS and P. GHIA.
Edition Leukemia, London, Nature Publishing Group, 2021, 0887-6924.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 12.883
RIV identification code RIV/00216224:14110/21:00123869
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1038/s41375-021-01450-8
UT WoS 000713599200001
Keywords in English COVID-19; severity; mortality; CLL
Tags 14110212, 14110323, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 20/1/2022 14:42.
Abstract
Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.
PrintDisplayed: 10/7/2024 05:49